Patient Search
 |
 |
|
KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story |
If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story. https://momentum.vicc.org/2022/04/brighter-outlook/ |
A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em
Thyroid
Thyroid
Thyroid
III
Choe, Jennifer
NCT06475989
ECOGHNEA3231
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast
Breast
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Breast
III
Abramson, Vandana
NCT07085767
VICCBRE25043
E-Mindfulness Approaches for Living After Breast Cancer
Breast
Breast
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.
Breast
III
Kennedy, Laura
NCT06748222
NRGBRECC015
Optimice-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Breast
Breast
Breast
III
Abramson, Vandana
NCT05812807
VICC-NTBRE23357
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Prostate
Prostate
Prostate
III
Schaffer, Kerry
NCT06592924
ALLUROCCTGPR26
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk Retroperitoneal Sarcoma (STRASS 2)
Sarcoma
Sarcoma
Sarcoma
III
Davis, Elizabeth
NCT04031677
ECOGSAREA7211
Elacestrant Versus Standard Endocrine Therapy in Women and Men with Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer with High Risk of Recurrence-A Global, Multicenter, Randomized, Open-Label Phase 3 Study
Breast
Breast
Breast
III
Abramson, Vandana
NCT06492616
VICC-DTBRE24171
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
Myelodysplastic Syndrome
Myelodysplastic Syndrome
Myelodysplastic Syndrome
III
Kishtagari, Ashwin
NCT06499285
VICCHEM24599
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Multiple Cancer Types
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Leukemia,
Lymphoma
III
Dholaria, Bhagirathbhai
NCT06615050
VICC-DTCTT23454
An Open-Label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given with or without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
Not Available
III
Not Available
NCT05253651
VICC-DTGIT23052
